share_log

Critical Analysis: Heska (NASDAQ:HSKA) & Cardio Diagnostics (NASDAQ:CDIO)

Critical Analysis: Heska (NASDAQ:HSKA) & Cardio Diagnostics (NASDAQ:CDIO)

关键分析:Heska(纳斯达克股票代码:HSKA)和有氧诊断(纳斯达克股票代码:CDIO)
Financial News Live ·  2023/01/15 02:41

Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Heska (NASDAQ:HSKA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

心脏诊断(纳斯达克:CDIO-GET评级)和赫斯卡(纳斯达克:HSKA-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的收益、盈利能力、风险、分析师建议、股息、估值和机构所有权等方面的实力进行比较。

Institutional & Insider Ownership

机构与内部人持股

77.3% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 99.0% of Heska shares are owned by institutional investors. 11.0% of Heska shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardio Diagnostics 77.3%的股份由机构投资者持有。相比之下,赫斯卡99.0%的股份由机构投资者持有。赫斯卡11.0%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一只股票有望实现长期增长。

Get
到达
Cardio Diagnostics
心脏诊断学
alerts:
警报:

Profitability

盈利能力

This table compares Cardio Diagnostics and Heska's net margins, return on equity and return on assets.

此表比较了Cardio Diagnostics和Heska的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Cardio Diagnostics N/A N/A N/A
Heska -6.26% 0.09% 0.06%
净利润率 股本回报率 资产回报率
心脏诊断学 不适用 不适用 不适用
赫斯卡 -6.26% 0.09% 0.06%

Analyst Ratings

分析师评级

This is a breakdown of current ratings and target prices for Cardio Diagnostics and Heska, as provided by MarketBeat.
这是MarketBeat提供的Cardio Diagnostics和Heska的当前评级和目标价格的细目。
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics 0 0 0 0 N/A
Heska 1 0 3 0 2.50
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
心脏诊断学 0 0 0 0 不适用
赫斯卡 1 0 3 0 2.50

Cardio Diagnostics currently has a consensus price target of $8.00, suggesting a potential upside of 525.00%. Heska has a consensus price target of $123.00, suggesting a potential upside of 56.77%. Given Cardio Diagnostics' higher possible upside, equities research analysts clearly believe Cardio Diagnostics is more favorable than Heska.

心脏诊断公司目前的共识目标价为8.00美元,暗示潜在上涨525.00%。赫斯卡的一致目标价为123.00美元,暗示潜在上行空间为56.77%。鉴于Cardio Diagnostics较高的可能上行空间,股票研究分析师显然认为Cardio Diagnostics比Heska更有利。

Earnings & Valuation

收益与估值

This table compares Cardio Diagnostics and Heska's top-line revenue, earnings per share and valuation.

此表比较了Cardio Diagnostics和Heska的营收、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardio Diagnostics N/A N/A -$140,000.00 N/A N/A
Heska $253.74 million 3.35 -$1.15 million ($1.57) -49.97
总收入 价格/销售额比 净收入 每股收益 市盈率
心脏诊断学 不适用 不适用 -$140,000.00 不适用 不适用
赫斯卡 2.5374亿美元 3.35 -115万美元 ($1.57) -49.97

Cardio Diagnostics has higher earnings, but lower revenue than Heska.

心脏诊断公司的收益比赫斯卡高,但收入比赫斯卡低。

Summary

摘要

Heska beats Cardio Diagnostics on 6 of the 9 factors compared between the two stocks.

赫斯卡在两只股票比较的9个因素中有6个击败了Cardio Diagnostics。

About Cardio Diagnostics

关于Cardio诊断公司

(Get Rating)

(获取评级)

Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.

心脏诊断控股公司是一家生物技术公司,开发和商业化基于表观遗传学的心血管疾病临床测试。它提供Epi+Gen,这是一种为期三年的症状性冠心病(CHD)风险评估测试,针对包括心脏病发作在内的CHD事件。该公司成立于2017年,总部位于伊利诺伊州芝加哥。

About Heska

关于赫斯卡

(Get Rating)

(获取评级)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

赫斯卡公司为美国、加拿大、墨西哥、澳大利亚、法国、德国、意大利、马来西亚、西班牙和瑞士的狗和猫保健市场销售兽医和动物健康诊断和特种产品。公司提供用于血液化学和电解质分析的Element DC、Element DCX、Element DC5x;用于血液化学和电解质分析的Element RC、Element RCX和Element RC3X化学系统;用于测量血细胞、血小板计数和血红蛋白水平的Element HT5和Element Vet ABC Plus;Element POC血气和电解质分析仪;Element I免疫诊断分析仪;Element COAG和Element AIM兽医分析仪。该公司还提供HeskaView Telecytotology,提供临床自动化显微镜载片扫描和计算设备;静脉输液泵;数字放射硬件和移动数字放射产品;超声波系统;基于Web的图像存储解决方案Cloudbank;用于检测与动物传染病和寄生虫病相关的抗原和抗体的护理点产品;用于治疗犬心虫感染、蛔虫和钩虫感染的Tri-Heart Plus咀嚼片;以及过敏产品和服务,包括ALLERCEPT明确过敏原面板,以及治疗针剂或滴剂。此外,该公司还为其他动物保健公司提供一系列牛疫苗、生物和医药产品,以及包括研究、许可、生产、标签和包装在内的交钥匙服务,以及验证支持和分销服务。它通过电话销售队伍和第三方分销商向兽医销售产品,并通过贸易展、平面广告和其他分销关系销售产品。该公司前身为Paravax, 并于1995年更名为赫斯卡公司。该公司成立于1988年,总部设在科罗拉多州的洛夫兰。

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

接收《心脏诊断日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cardio Diagnostics和相关公司的最新新闻和分析师评级的每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发